Mymetics Corp (MYMX)

[Work Harder]

Epalinges, Switzerland-based Anergis is now talking both to potential licensees and to its investors about financing a pivotal Phase III trial. “We are looking at two scenarios, finding a pharma partner or funding it ourselves. It’s hard to say at the moment which way we will go, Charlon said.

The aim is that the Phase III trial, involving 400 to 600 patients, is agreed to in time to treat patients at the end of 2014. They will then be followed in the 2015 birch pollen season, beginning about March/April. The company also is looking at the possibility of conducting a similar trial in the U.S. in the 2016 pollen season.

In a sign of increasing interest in the allergy market DBV Technologies SA last week announced a licensing deal on a treatment for birch pollen allergy with Stallergenes SA, worth up to €145 million (US$198 million) in milestone payments, with royalties on sales to follow if a product makes it to market. (See BioWorld Today, Oct. 21, 2013).

https://www.bioworld.com/articles/346477-anergis-preps-for-pivotal-trial-of-allergy-vaccine-seeks-partner

Under the terms of this agreement, Stallergenes will fully fund DBV’s pre-clinical development. The goal of the preclinical
program, which will last between 18 and 24 months is for DBV to deliver to Stallergenes a clinical product candidate that
uses Stallergenes’ Birch pollen allergen. Stallergenes will have full development and worldwide commercialization rights on
the product candidate, and DBV is eligible to receive several preclinical, clinical, regulatory and commercial milestone
payment totaling up to €145 million, as well as royalties on the future product’s net sales.

In conjunction with this agreement, Stallergenes acquires a 2.0% equity position in DBV from existing shareholders

https://www.dbv-technologies.com/wp-content/uploads/2017/09/970pr_dbv_stallergen_announce-respitato-1.pdf